EDITAS MEDICINE, INC. Lease Obligation Incurred
EDITAS MEDICINE, INC. (EDIT) reported Lease Obligation Incurred of $3.78 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-05.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2023-05-05
- EDITAS MEDICINE, INC. lease obligation incurred for the quarter ending 2023-03-31 was $3.78M.
- EDITAS MEDICINE, INC. lease obligation incurred for the quarter ending 2016-12-31 was $3.35M.
- EDITAS MEDICINE, INC. lease obligation incurred for the quarter ending 2016-09-30 was $9.92M.
- EDITAS MEDICINE, INC. lease obligation incurred for the quarter ending 2016-06-30 was $11.03M.
- EDITAS MEDICINE, INC. lease obligation incurred for fiscal 2016 was $35.94M.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 6 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|---|
| 2023-03-31 | $3.78M 10-Q · filed 2023-05-05 | |||
| 2016-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $13.27M derived: sum of 2 quarters · filed 2018-03-08 | $24.29M derived: sum of 3 quarters · filed 2018-03-08 | $35.94M 10-K · filed 2018-03-08 |
| 2016-09-30 | $9.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $20.95M derived: sum of 2 quarters · filed 2016-11-09 | $32.59M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $11.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $22.68M 10-Q · filed 2016-08-10 | ||
| 2016-03-31 | $11.65M 10-Q · filed 2016-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |